<DOC>
	<DOCNO>NCT01915459</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy Botulax® compare Botox® reduce upper limb muscle tone post stroke patient .</brief_summary>
	<brief_title>Phase III Study Botulax® Treat Post Stroke Upper Limb Spasticity</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>1 . Male Female patient , 20 year age 2 . Patients history stroke 6weeks prior enrollment 3 . Focal spasticity wrist flexor measure Modified Ashworth Scale ( MAS ) 2 great wrist 1 great least one elbow flexor finger flexor 4 . A minimum grade 2 great Disability Assessment Scale ( DAS ) target one functional disability item ( i.e. , hygiene , dress , pain , limb position ) 5 . Patients sign informed consent form , clearly understand intent study able comply instruction complete entire study 1 . Patients diagnose neuromuscular disorder LamberEaton syndrome , myasthenia gravis , amyotrophic lateral sclerosis 2 . Patients profound atrophy muscle target limb 3 . Patients fixed joint/muscle contracture* target limb Defined inability passively move joint 4 . Patients history within 6 month plan treatment phenol alcohol injection ( chemodenervation ) target limb 5 . Patients history within 6 month plan treatment tendon lengthen target limb 6 . Patients concurrent treatment intrathecal baclofen 7 . Patients receive Botulinum toxin injection within past 3 month ( cosmetic purpose allow ) 8 . Patients concurrent plan take muscle relaxant and/or benzodiazepine medication ( Allowed participate patient consistently take medication month screen visit change therapy plan study ) 9 . Patients concurrent planned physical , occupational , splint therapy ( Allowed participate therapy consistently take month screen visit treatment change plan study 10 . Patients know allergy sensitivity study medication component ( Clostridium botulinum toxin type A , albumin , Sodium chloride , etc . ) 11 . Patients participate clinical trial 1 month prior study 12 . Male Female willing take appropriate mean contraception ascetic life least 2 month treatment 13 . Patients eligible study discretion investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Stroke</keyword>
	<keyword>Spasticity</keyword>
</DOC>